Detalhe da pesquisa
1.
The Acute Stroke Therapy by Inhibition of Neutrophils study - Key features and impact.
Pharm Stat
; 21(4): 720-728, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35819119
2.
Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job.
Ann Intern Med
; 172(2): 119-125, 2020 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31739312
3.
Lessons from meta-analyses of randomized clinical trials for analysis of distributed networks of observational databases.
Pharm Stat
; 18(1): 65-77, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30362223
4.
Changes are still needed on multiple co-primary endpoints.
Stat Med
; 36(28): 4427-4436, 2017 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28722159
5.
A comparison of five approaches to decision-making for a first clinical trial of efficacy.
Pharm Stat
; 16(1): 37-44, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27678332
6.
Implementation of AMNOG: An industry perspective.
Biom J
; 58(1): 76-88, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26332597
7.
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).
Clin Infect Dis
; 61(5): 800-6, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26113652
8.
The shrinking or disappearing observed treatment effect.
Pharm Stat
; 13(5): 277-80, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25182453
9.
Subgroup analyses in cost-effectiveness analyses to support health technology assessments.
Pharm Stat
; 13(4): 265-74, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24931490
10.
The practice of pre-marketing safety assessment in drug development.
J Biopharm Stat
; 23(1): 3-25, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23331218
11.
Designing studies to find early signals of efficacy.
J Biopharm Stat
; 22(6): 1097-108, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23075010
12.
A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
Clin Trials
; 8(1): 5-14, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21335586
13.
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies.
Pharm Stat
; 10(1): 3-7, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-20073040
14.
The role of the minimum clinically important difference and its impact on designing a trial.
Pharm Stat
; 10(3): 250-6, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-20936625
15.
Subgroup analyses of clinical effectiveness to support health technology assessments.
Pharm Stat
; 10(6): 532-8, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22140066
16.
Commentary: preserving confidentiality of interim data.
Clin Trials
; 12(1): 18-20, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25480540
17.
FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
J Biopharm Stat
; 20(6): 1143-9, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21058110
18.
Determining a minimum clinically important difference between treatments for a patient-reported outcome.
J Biopharm Stat
; 20(5): 1043-54, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20721790
19.
Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
J Biopharm Stat
; 20(6): 1115-24, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21058107
20.
University of Pennsylvania 6th annual conference on statistical issues in clinical trials: Dynamic treatment regimes (afternoon session).
Clin Trials
; 11(4): 457-466, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25053777